Filing Details

Accession Number:
0001209191-16-134702
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-01 18:43:58
Reporting Period:
2016-07-29
Filing Date:
2016-08-01
Accepted Time:
2016-08-01 18:43:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1299130 Pacific Biosciences Of California Inc. PACB Laboratory Analytical Instruments (3826) 161590339
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1504238 Michael James Phillips Pacific Biosciences Of California, Inc.
1380 Willow Road
Menlo Park CA 94025
Svp, Research & Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-07-29 17,500 $1.96 198,949 No 4 M Direct
Common Stock Acquisiton 2016-07-29 2,500 $2.18 201,449 No 4 M Direct
Common Stock Disposition 2016-07-29 20,000 $8.45 181,449 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2016-07-29 17,500 $0.00 17,500 $1.96
Common Stock Stock Option (right to buy) Disposition 2016-07-29 2,500 $0.00 2,500 $2.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-06-21 No 4 M Direct
97,500 2014-02-15 2023-02-15 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. This is the weighted average price of the shares sold, which ranged from $8.29 to $8.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. 100% of the shares subject to the option were fully vested and exercisable.
  4. 1/5th of the shares subject to the option vested on February 15, 2014 and the balance of the shares vest monthly thereafter over the next four years, provided that the Reporting Person continues to serve through each vesting date.